Skip to main content
. 2021 Mar 18;11:630825. doi: 10.3389/fphar.2020.630825

TABLE 1.

Characteristics of RCTs included in the study.

Study Sample size(E/C) Age Sex(Man/Feman) Clinical stage Pathological type Experiment Group(E) Control Group(C) Treatment Cycle First Treatment Outcome
Chen and Li (2012) 35/35 55.5/60.5 24/11; III 14,IV 21; S20,A15; Rg3 20 mg GP 6-9 weeks NO Efficac ( RECIST ); Adverse reactions; KPS
22/13 III 13,IV 22 S18,A17 po.bid +C
Chen et al. (2014) 34/34 4 1 ∼ 7 3 39/29 IIIB-IV A26,S21,AC18,B3 Rg3 20 mg TP 12 weeks No Efficacy(RECIST); Adverse reactions; Immune index
po.bid +C
Du (2014) 30/30 40.2 ± 3.6 31/29 advanced NSCLC Rg3 20 mg TP 6 weeks No Efficacy(RECIST);KPS
po.bid +C
Li and Bai (2017) 90/90 57 ± 1. 3/58 ± 1. 0 49/41; advanced NSCLC Rg3 20 mg GP 9 weeks No Efficacy(RECIST); PFS,OS; Adverse reactions
49/41 po.bid +C
Li et al. (2012) 39/38 - - advanced A23,S14,B2;A20,S16,B2 Rg3 20 mg GP 6 weeks No Efficacy(RECIST); KPS;Adverse reactions PFS;one-year survival rate
po.bid +C
Liang and Han (2016) 47/46 67.47 ± 7.74/66. 32 ± 6. 21 34/13; IIIA-IV NSCLC Rg3 20 mg GP 12 weeks No KPS;Adverse reactions
31/15 po.bid +C
Lin et al. (2014) 33/25 65-85 32/26 IIIA6,IIIB6,IV46 A44,S8,P6 Rg3 20 mg PC 6 weeks No Efficacy(RECIST); KPS;Adverse reactions
po.bid +C
Liu et al. (2007) 35/35 35-70 43/27 IIIB-IV S26,A40,B4 Rg3 20 mg NP 6 weeks Yes Efficacy(WHO); KPS;Adverse reactions;Immune index
po.bid +C
Liu et al. (2009) 34/30 43-75/31-66 26/8;19/11 IIIB22,IV12/IIIB26,IV4 A21,S9,AC4/A21,S6,AC2,B1 Rg3 20 mg NP 6 weeks No Efficacy(WHO);Adverse reactions;one-year survival rate
po.bid +C
Liu et al. (2015) 60/60 52.5 ± 2.0/54.6 ± 2.1 46/14;35/25 III37,IV23/III29,IV31 A19,S41/A13,S46 Rg3 20 mg NP - No Efficacy(unclear);Adverse reactions
po.bid +C
Pan and Wu (2016) 24/24 71.5/71 16/8;15/9 advanced unclear Rg3 20 mg TP 6 weeks No Efficacy(RECIST); KPS;Adverse reactions
po.bid +C
Pan et al. (2019) 103/104 60.6 ± 10.4/62.5 ± 11.9 53/50;51/53 III-IV unclear Rg3 20 mg TP 9 weeks Yes Efficacy(RECIST); KPS;Immune index
po.bid +C
Pang (2012) 22/21 63.95 26/17 IIIB13,IV30 A26,S18 Rg3 20 mg GP/PC/TP 6 weeks Yes Efficacy(RECIST); KPS;Adverse reactions
po.bid +C
Qi and Zhang (2011) 35/35 37-70 48/22 advanced A40,S26,B4 Rg3 20 mg GP 6 weeks Yes Efficacy(unclear); KPS;Adverse reactions
po.bid +C
Shen et al. (2018) 25/27 66-78/66-77 14/11;17/10 IIIB-IV A15,S10/A19,S8 Rg3 20 mg GP/PC 6 weeks Yes Efficacy(WHO); Adverse reactions;one-year survival rate
po.bid +C
Sun et al. (2006) 51/50 59.54/57.44 40/14;39/22 III21,IV33/III24,IV37 S16,A27,AC6,05;S13,A44,AC2,O2 Rg3 20 mg NP 6 weeks No Efficacy(WHO); Adverse reactions; PFS
po.bid +C
Tu (2018) 21/20 - 13/8;11/9 III7,IV14;III8,IV12 A10,S7,04;A9,S9,02 Rg3 20 mg TP 6 weeks Yes Efficacy(RECIST); KPS;VEGF
po.bid +C
Wang et al. (2020) 39/39 54.9 ± 8.1/55.6 ± 7.8 21/18;22/17 IIIB18,IV21;IIIB19,IV20 A20,S19;A21,S18 Rg3 20 mg GP/PC 6 weeks No Efficacy(WHO); Adverse reactions
po.bid +C
Wang et al. (2011) 59/58 53 74/43 IIIB-IV A31,S28/A37,S21 Rg3 20 mg GP/NP - Yes VEGF;KPS;Adverse reactions
po.bid +C
Wang et al. (2017) 45/44 58. 95 52/37 IIIb41,IV48 A58,S31 Rg3 20 mg TP/PC/GP/NP 6 weeks No Efficacy(unclear);KPS;Adverse reactions
po.bid +C
Zhang et al. (2020) 41/41 71. 34 ± 4. 25/71. 52 ± 3. 65 27/14;26/15 IIIb18,IV23/IIIb17,IV24 UNCLEAR Rg3 20 mg GP 12 weeks No Efficacy(WHO);KPS;Immune index; Adverse reactions
po.bid +C
Zhang et al. (2018) 199/215 61.16 ± 10.41/60.76 ± 10.39 128/71;161,64 IIIA25,IIIB74,IV100/IIIA20,IIIB73,IV122 A114,S65,B3,017/A121,S72,B3,O19 Rg3 20 mg NP/TP ≥6 weeks Yes Adverse reactions
po.bid +C

S, squamous cell carcinoma; A, adenocarcinoma; AC, adenosquamous carcinoma; B, large cell carcinoma; O, poorly differentiated carcinoma; GP, gemcitabine; TP, PTX; PC, pemetrexeddisodium; NP, navelbine.